Is AbbVie A Buy Following The Share Price Slump?


  • AbbVie has seen its shares pull back in recent weeks.
  • Humira has gone off patent in the US, but other assets are generating strong growth.
  • AbbVie is not expensive and offers a compelling dividend yield.

Abbott and Abbvie sign at their headquarters in Abbott Park, IL, USA.


Article Thesis

AbbVie (NYSE:ABBV) has seen its shares pull back by close to 20% over the last couple of weeks. This coincides with the rollout of biosimilars to AbbVie’s blockbuster drug Humira. But that was a very well-known factor for

Data by YCharts


AbbVie presentation

Disclosure: I/we have a beneficial long position in the shares of ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Is This an Income Stream Which Induces Fear?

image.pngThe primary goal of the Cash Flow Kingdom Income Portfolio is to produce an overall yield in the 7% – 10% range. We accomplish this by combining several different income streams to form an attractive, steady portfolio payout. The portfolio’s price can fluctuate, but the income stream remains consistent. Start your free two-week trial today!

Leave a Reply

Your email address will not be published. Required fields are marked *